摘要
目的：探讨阿立哌唑口崩片与利培酮治疗精神分裂症患者的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组，每组30例，研究组口服阿立哌唑口崩片治疗，对照组口服利培酮片治疗，观察12周。治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前显著下降（P＜0.01），治疗各时点两组评分比较差异均无显著性（P＞0.05），治疗12周末研究组有效率86.7％，对照组为83.3％，两组比较差异无显著性（ P＞0.05）。两组不良反应均轻微，研究组治疗第12周末副反应量表评分显著低于对照组（ P＜0.05）。结论阿立哌唑口崩片与利培酮治疗精神分裂症疗效显著且相当，但阿立哌唑口崩片安全性更高，依从性更好。
Objective To explore the clinical efficacy and safety of aripiprazole orally disintegrating tablets and risperidone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly divided into two groups of 30 ones each ,research group took orally aripiprazole orally disintegrating tablets and control group did risperidone 12 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results After treatment the total and each factor scores of the PANSS in both groups lowered more significantly compared with pretreatment （P〈0.01） ,there were no significant group differ‐ences in score at each time point （P〉0.05） ,at the end of the 12th week effective rate was respectively 86.7% in research and 83.3% in control group ,which showed no significant group difference （P〉0.05） . Adverse reactions of both groups were mild and at the end of the 12th week the TESS score was significant‐ly lower in research than control group （P〈 0.01） .Conclusion Both aripiprazole orally disintegrating tablets and risperidone have same notable efficacy in schizophrenia ,but the former has higher safety and better compliance .
出处
《临床心身疾病杂志》
CAS
2015年第2期51-53,共3页
Journal of Clinical Psychosomatic Diseases
